About this document
Zydus Lifesciences Q2 FY26 Investor Update by shashivicky123 is a document available to read on EtoBox.
Zydus Lifesciences Limited reported robust growth in its unaudited financial results for Q2 FY26, with total revenues increasing by 17% year-over-year. Key highlights include a strong performance in India branded formulations, a successful acquisition of Comfort Click Ltd, and a notable EBITDA margin of 32.9%. The company also achieved significant growth in its US formulations and international markets, while maintaining a focus on innovation and expansion.
- Author
- shashivicky123
- Language
- EN